Literature DB >> 12154063

The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene.

Roberto Diaz1, Daniel Ahn, Lluis Lopez-Barcons, Marcos Malumbres, Ignacio Perez de Castro, Jeffrey Lue, Neus Ferrer-Miralles, Ramon Mangues, Jerry Tsong, Roberto Garcia, Roman Perez-Soler, Angel Pellicer.   

Abstract

ras proto-oncogenes have traditionally been associated with the regulation and promotion of cell growth. We have induced thymic lymphomas in N-ras(-/-) mice and in transgenic mice that overexpress wild-type N-ras and found that the lack of wild-type N-ras alleles favors the development of thymic lymphomas,whereas overexpression of wild-type N-ras protects against thymic lymphomagenesis in the presence or absence of its oncogene. To investigate the inhibitory role of wild-type N-ras in in vitro transformation, we introduced wild-type N-ras in N-ras-deficient tumor cells that lack ras activating mutations and found decreased growth in both low serum and soft agar. Taken together, our results indicate that wild-type N-ras has "tumor suppressor" activity, even in the absence of its oncogenic allele.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12154063

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Wild-type NRas and KRas perform distinct functions during transformation.

Authors:  Poppy P Fotiadou; Chiaki Takahashi; Hasan N Rajabi; Mark E Ewen
Journal:  Mol Cell Biol       Date:  2007-07-16       Impact factor: 4.272

2.  Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.

Authors:  G Kong; Y-I Chang; A Damnernsawad; X You; J Du; E A Ranheim; W Lee; M-J Ryu; Y Zhou; Y Xing; Q Chang; C E Burd; J Zhang
Journal:  Leukemia       Date:  2016-02-29       Impact factor: 11.528

3.  Wild type N-ras displays anti-malignant properties, in part by downregulating decorin.

Authors:  Marta Benet; Robin Yates Dulman; Raffi Suzme; Eleazar Vega-Saenz de Miera; Martha E Vega; Thuy Nguyen; Jiri Zavadil; Angel Pellicer
Journal:  J Cell Physiol       Date:  2012-06       Impact factor: 6.384

4.  Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.

Authors:  Jinyong Wang; Yangang Liu; Zeyang Li; Zhongde Wang; Li Xuan Tan; Myung-Jeom Ryu; Benjamin Meline; Juan Du; Ken H Young; Erik Ranheim; Qiang Chang; Jing Zhang
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

5.  Growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line.

Authors:  Hong Li; Hou-Fa Cao; Jun Wan; Yuan Li; Mei-Ling Zhu; Po Zhao
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

Review 6.  The Mystery of Rap1 Suppression of Oncogenic Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Mingzhen Zhang; Chung-Jung Tsai; Anna A Sablina
Journal:  Trends Cancer       Date:  2020-03-02

7.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.

Authors:  Hensin Tsao; Vikas Goel; Heng Wu; Guang Yang; Frank G Haluska
Journal:  J Invest Dermatol       Date:  2004-02       Impact factor: 8.551

Review 8.  The role of wild type RAS isoforms in cancer.

Authors:  Bingying Zhou; Channing J Der; Adrienne D Cox
Journal:  Semin Cell Dev Biol       Date:  2016-07-13       Impact factor: 7.727

9.  Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene.

Authors:  Xu Chen; Norisato Mitsutake; Krista LaPerle; Nagako Akeno; Pat Zanzonico; Valerie A Longo; Shin Mitsutake; Edna T Kimura; Hartmut Geiger; Eugenio Santos; Hans G Wendel; Aime Franco; Jeffrey A Knauf; James A Fagin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-29       Impact factor: 11.205

10.  Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.

Authors:  Erin Sheffels; Nancy E Sealover; Chenyue Wang; Do Hyung Kim; Isabella A Vazirani; Elizabeth Lee; Elizabeth M Terrell; Deborah K Morrison; Ji Luo; Robert L Kortum
Journal:  Sci Signal       Date:  2018-09-04       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.